Citation Impact
Citing Papers
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia
2003 Standout
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
2015
Bayes Factors
1995 Standout
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
2016
Beyond Antibodies: The DARPin® Drug Platform
2020
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
2020
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
1992 StandoutNature
Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors
1997
HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas
2005 StandoutNobel
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
1996 Standout
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Liquid biopsy enters the clinic — implementation issues and future challenges
2021
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
2004 Standout
Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis
2001 StandoutNobel
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
The biology of VEGF and its receptors
2003 Standout
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
2006 Standout
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
Lung cancer: current therapies and new targeted treatments
2016 Standout
VEGF receptor signalling ? in control of vascular function
2006 Standout
Antiangiogenic therapy—evolving view based on clinical trial results
2012
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
2012
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
1994 Standout
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
2010 Standout
Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia
2000 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
2012 Standout
Gastric cancer
2020 Standout
De novo design of buttressed loops for sculpting protein functions
2024 StandoutNobel
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Fibroblasts in cancer
2006 Standout
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
2000 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Large-scale brain networks and psychopathology: a unifying triple network model
2011 Standout
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
2020 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
1999 Standout
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
2015
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
1996 Standout
Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF
1989 StandoutScience
Utility of Humanized BLT Mice for Analysis of Dengue Virus Infection and Antiviral Drug Testing
2013 StandoutNobel
High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients
2014
Clinical trials in psychiatry
1983
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
2020
The Biology of Vascular Endothelial Growth Factor
1997 Standout
The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
1992 StandoutScience
The Next Decade of Immune Checkpoint Therapy
2021 Nobel
Bayesian Methods in Practice: Experiences in the Pharmaceutical Industry
1986
HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation
2015
Angiogenic Factors
1987 StandoutScience
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
1983 StandoutScience
Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1lowand immune desert‑like mouse tumors
2021
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation
1992 Standout
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
2015
Tumors: Wounds That Do Not Heal
1986 Standout
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
1995 Standout
Expression of hypoxia-inducible factor 1? in brain tumors
2000 StandoutNobel
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
1991 Standout
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
2015
Vascular endothelial growth factor (VEGF) and its receptors
1999 Standout
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Works of Davey B. Daniel being referenced
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
2019
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
2019
EVALUATION OF THE ROLE OF HISTAMINE H1AND H2‐RECEPTORS IN CUTANEOUS INFLAMMATION IN THE GUINEA‐PIG PRODUCED BY HISTAMINE AND MAST CELL DEGRANULATION
1980
Two open-label, long-term safety studies of sertindole
1996
First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.
2019
Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)
2017
Further Analysis of the Hills and Armitage Enuresis Data
1981
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
2013
Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
2011